Cholesterol Overload Drives Hepatic Steatosis by Inhibiting OGT-dependent PPARα O-GlcNAcylation and Transactivation
Authors:
Open Access
- 18 May 2026
- journal article
- research article
- Published by Ivyspring International Publisher in International Journal of Biological Sciences
- Vol. 22 (11) , 5615-5633
Abstract
Although dietary cholesterol is known to exacerbate liver disease progression, whether and how it contributes to hepatic steatosis, the hallmark early pathological feature of both MASLD and ALD, remains poorly understood. Here, we investigated how cholesterol disrupts hepatic triacylglycerol metabolism using both dietary and cellular cholesterol-loading models. Integrated transcriptomic, metabolomic, and biochemical analyses were performed, and causality was examined through genetic and pharmacologic modulation in multiple hepatocyte systems and mice. Our results demonstrate that cholesterol overload induces hepatocellular fat accumulation in a dose-dependent, cell-autonomous manner, primarily by suppressing fatty acid β-oxidation. Mechanistically, we identified PPARα inhibition as a key event underlying this effect. Cholesterol overload suppressed PPARα transactivation, thereby impairing fatty acid β-oxidation and promoting hepatocellular fat accumulation. This inhibition was mechanistically linked to reduced O-GlcNAcylation. Specifically, cholesterol overload downregulated OGT, leading to reduced protein O-GlcNAcylation and consequent PPARα inhibition; similarly, liver-specific OGT knockout mice exhibited suppressed PPARα activity and increased hepatic fat accumulation. RNA-sequencing and co-immunoprecipitation analyses identified PPARα as an O-GlcNAc-modified protein, and loss of this modification impaired its transactivity. Functionally, restoration of O-GlcNAcylation via genetic OGA knockdown or pharmacological activation of PPARα with WY14643 alleviated cholesterol-induced hepatic steatosis in mice without altering hepatic cholesterol levels. Lastly, we identified SREBP2 as the upstream transcriptional regulator linking cholesterol overload to OGT suppression. In conclusion, our findings in this study uncover a previously unrecognized cholesterol-OGT-PPARα axis that suppresses hepatic fatty acid β-oxidation and drives steatosis. Targeting O-GlcNAc cycling or activating PPARα represents a promising therapeutic strategy for MASLD.Keywords
This publication has 53 references indexed in Scilit:
- Integrated physiology and systems biology of PPARαMolecular Metabolism, 2014
- Increased De Novo Lipogenesis Is a Distinct Characteristic of Individuals With Nonalcoholic Fatty Liver DiseaseGastroenterology, 2014
- Nutrient-driven O-GlcNAc cycling – think globally but act locallyJournal of Cell Science, 2014
- Protective Effects of Peroxisome Proliferator-Activated Receptor-αAgonist, Wy14643, on Hypoxia/Reoxygenation Injury in Primary Rat HepatocytesPPAR Research, 2011
- Hepatic Free Cholesterol Accumulates in Obese, Diabetic Mice and Causes Nonalcoholic SteatohepatitisGastroenterology, 2011
- The Role of PPARActivation in Liver and MusclePPAR Research, 2010
- PPAR/RXR Regulation of Fatty Acid Metabolism and Fatty Acidω‐Hydroxylase (CYP4) Isozymes: Implications for Prevention of Lipotoxicity in Fatty Liver DiseasePPAR Research, 2009
- Peroxisome Proliferator-Activated Receptor (PPAR)-α: A Pharmacological Target with a Promising FuturePharmaceutical Research, 2004
- Administration of the potent PPARα agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in miceHepatology, 2004
- Hepatic cholesterol and bile acid metabolism and intestinal cholesterol absorption in scavenger receptor class B type I-deficient miceJournal of Lipid Research, 2001